Balchem BCPC
- Market cap
- $5.6B
- PE
- 34.8×
- 10y median 41.0×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 5.2×
- EV/EBIT
- 25.9×
- Revenue, 12 months
- $1.1B
- +9% on a year ago
- Net margin
- 15.1%
- Free cash flow yield
- n/m
- not a meaningful number
Balchem trades at 34.8× trailing earnings, cheaper than 84% of the last ten years. Revenue was $1.1B over the last twelve months, up 9% on a year earlier with a 15% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $228.7M−2% | $239.7M+3% | $234.1M+1% | $239.9M+4% | $240M+5% | $250.5M+5% | $255.5M+9% | $267.6M+12% | $263.6M+10% | $270.7M+8% | $284M+11% | $290.7M+9% | |
| Cost of revenue | $153.7M−6% | $158.1M−1% | $151.1M−2% | $154.6M+1% | $153.7M+0% | $162.4M+3% | $162.4M+8% | $172.1M+11% | $169.7M+10% | $169.6M+5% | $180.3M+11% | $184.9M+8% |
| Gross profit | $75M+9% | $81.5M+11% | $83M+7% | $85.4M+12% | $86.3M+15% | $88.2M+8% | $93.1M+12% | $95.5M+12% | $93.9M+9% | $101.1M+15% | $103.7M+11% | $105.7M+11% |
| R&D | $3.9M+29% | $4.1M+19% | $3.9M+2% | $4.3M+12% | $4.5M+15% | $4.7M+14% | $4.3M+12% | $4.5M+4% | $5.1M+12% | $5.9M+26% | $4.5M+5% | $5.3M+19% |
| SG&A | $32.7M+1% | $35.7M+1% | $33.3M+9% | $33M+14% | $34.4M+5% | $32.5M−9% | $37.4M+12% | $36.4M+10% | $36.6M+6% | $39.6M+22% | $39.9M+7% | $37.9M+4% |
| $38.3M+15% | $41.7M+21% | $45.8M+7% | $48M+10% | $47.4M+24% | $51M+22% | $51.4M+12% | $54.6M+14% | $52.3M+10% | $55.6M+9% | $59.2M+15% | $62.4M+14% | |
| Interest expense | $5.3M+3% | $5.4M−3% | $4.2M−18% | $4.1M−38% | $2.8M−47% | $2.9M−46% | $2.8M−35% | $2.6M−35% | $1.9M−33% | $2.2M−24% | $1.9M−30% | $1.9M−26% |
| Pre-tax income | $33.3M+29% | $36.9M+27% | $41.2M+7% | $43.9M+20% | $44.5M+34% | $47.9M+30% | $49M+19% | $52M+19% | $50M+13% | $52.5M+10% | $57.8M+18% | $60M+15% |
| $6.6M+52% | $7.9M+23% | $9.2M+11% | $10.1M+36% | $10.9M+65% | $10.9M+38% | $10.7M+17% | $11.8M+17% | $10.8M−1% | $12.2M+12% | $13.2M+23% | $13.3M+13% | |
| Net income | $26.6M+25% | $29M+28% | $32.1M+7% | $33.8M+16% | $33.6M+26% | $37.1M+28% | $38.3M+19% | $40.3M+19% | $39.2M+17% | $40.3M+9% | $44.6M+17% | $46.7M+16% |
| $0.82+24% | $0.89+27% | $0.98+5% | $1.03+14% | $1.03+26% | $1.13+27% | $1.17+19% | $1.24+20% | $1.21+18% | $1.25+11% | $1.39+19% | $1.46+18% | |
| 32.5M+0% | 32.6M+1% | 32.6M+1% | 32.8M+1% | 32.8M+1% | 32.8M+1% | 32.7M+0% | 32.6M−1% | 32.3M−2% | 32.3M−2% | 32.2M−2% | 32M−2% |
Diluted shares: 15 periods, Q4 FY11 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Chemicals nearest Balchem's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BCPCBalchem | $5.6B | 34.8× | 41.0× | 5.2× | +9% | 15.1% | |
| HXLHexcel | $6B | 40.0× | 35.9× | 3.0× | +5% | 7.8% | |
| CSWCSW Industrials | $4.8B | 40.6× | 34.7× | 4.1× | +28% | 10.3% | |
| EMNEastman Chemical | $7.4B | 16.9× | 13.4× | 0.8× | −5% | 5.0% | |
| ESIElement Solutions | $8.1B | 44.9× | 30.1× | 2.6× | +27% | 5.7% | |
| CBTCabot | $3.8B | 20.8× | 14.4× | 1.0× | −5% | 5.2% | |
| AVNTAvient | $3.8B | 22.2× | 20.2× | 1.1× | +2% | 5.1% | |
| ALBAlbemarle | $11.1B | 347× | 25.7× | 1.9× | +18% | 3.8% | |
| WDFCWD 40 | $2.9B | 32.3× | 39.2× | 4.2× | +10% | 13.2% | |
| FULFuller H B | $2.7B | 13.8× | 22.9× | 0.8× | +1% | 5.6% | |
| IOSPInnospec | $2.4B | 20.1× | 22.3× | 1.3× | +3% | 6.6% | |
| Peer median | $4.3B | 27.3× | 24.3× | 1.6× | +4% | 5.6% |
More on Balchem
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #2of 37Chemicals stocks with the highest profit margins
- #2of 13Chemicals stocks cheapest against their own PE history
- #6of 14Chemicals stocks with the fastest earnings growth
Its groups
About
- Industry
- Chemicals
- Sector
- Basic Materials
Valuation data, not investment advice. Prices as of .